FDA Brief

Warning letters Devices

FDA warning letter to

Koven Technologies, Inc.

High riskIssued Jul 21Posted Aug 4Center for Devices and Radiological Health

FDA warns Koven Technologies that its Bidop 3 Doppler was labeled for fetal use without clearance and had quality system violations.

What happened

FDA inspected Koven's Saint Louis, MO facility from February 2, 2026, through February 6, 2026, and found the Bidop 3 operations manual listed fetal heart sounds as an indication although that use was not cleared. FDA also found missing design-change records, no fetal risk analysis, weak contract-manufacturer oversight, and returned device failures not handled as complaints. Koven responded on February 27, April 17, and May 28, 2026; FDA says it cannot determine adequacy yet and the recall is ongoing.

What FDA found

  1. Koven did not document or approve design changes expanding the Bidop 3's labeled use to fetal heart sounds, and did not evaluate whether a new FDA clearance was needed.

    ISO 13485:2016 Clause 7.3.9
  2. Risk management reports for Bidop 3 and Bidop 7 did not assess fetal-specific hazards such as ultrasound exposure or misreading maternal signals as fetal heartbeat.

    ISO 13485:2016 Clause 7.1
  3. Koven lacked adequate criteria and an audit for a critical contract manufacturer, and did not control labeling or design changes made by that supplier.

    ISO 13485:2016 Clause 7.4.1
  4. Koven did not treat returned devices with performance failures as complaints or keep records of complaint review and investigation.

    21 CFR 820.35(a)

What FDA wants

FDA asks Koven to reply in writing within 15 business days with steps taken, documentation of corrections and corrective actions, and a timetable for any work not finished.

Who should pay attention

  • brands that buy Doppler ultrasound devices from contract manufacturers
  • device firms that rely on suppliers for labeling or design changes
  • quality teams managing FDA device clearances and complaint handling

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  4. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk